Dr. Chapa’s OBGYN Clinical Pearls

Latest Episodes:

Do Unintended Uterine Extensions Increase Rupture? May 09, 2026

Show notes

Uterine hysterotomy unintended extensions happen. For sure. This has been analyzed over many years, and it is still making news. Look at this mini-timeline: Back in 2018, authors published “Unintended hysterotomy extension during caesarean delivery: risk factors and maternal morbidity”. Moving up the timeline to 2020, others published in J Maternal-Fetal Neonatal Medicine, “Risk factors for uterine incision extension during cesarean delivery”. Then in 2024, in the PINK journal, authors published a related study, “The association between unintended hysterotomy extensions with cesarean delivery and subsequent preterm birth”. In this episode, we will review a new narrative review (in the Green Journal, May 3, 2026) of unintended hysterotomy extension at C-section. We will summarize known risk factors and focus on subsequent uterine rupture risk. Does unintended hysterotomy extension at CS increase TOLAC uterine rupture? It’s complicated. Listen in for details.

1. Giugale LE, Sakamoto S, Yabes J, Dunn SL, Krans EE. Unintended hysterotomy extension during caesarean delivery: risk factors and maternal morbidity. J Obstet Gynaecol. 2018 Nov;38(8):1048-1053.

2. Epub: Unintentional Extensions of the Cesarean Hysterotomy Incision. A Review and Proposed Classification System (May 3, 2026)

Weird cfDNA Results and ISSUES: May 2026 Data May 06, 2026

Show notes

Genome-wide noninvasive prenatal testing (GW-NIPT) was introduced in 2015 and became widely available in 2019. Nonetheless, we are still learning more about this important prenatal screening test. In January 2026, the ACOG released a new PA on this, which we will also review in this episode. Our main publication ti review, however, will be the AJOG May 2026’s systematic review and meta-analysis on the finding of “genome-wide” cfDNA discordant results and what this may mean for the pregnancy. Although rare, this may lead (over a third of cases) to some adverse perinatal issues. Listen in for details.

1. ACOG PA Jan 2026: Screening for Fetal Chromosomal Abnormalities

2. AJOG May 2026: https://click.notification.elsevier.com/CL0/https:%2F%2Fwww.ajog.org%2Farticle%2FS0002-9378(25)00865-8%2Ffulltext%3Fdgcid=raven_jbs_etoc_email/1/0100019d9ec37d7b-c586438d-021a-4097-8db3-c158e6f97c9b-000000/Vq6ksekOuvTxcv8OEZZ2uBesCg_hG6qlhqU_BlCnAK4=452

GLP1 Periconception Exposure and OB Outcomes May 04, 2026

Show notes

There is no denying it, you know of one or MORE individuals or patients currently on a GLP1 agent. Although not FDA approved for PCOS as a stand-alone diagnosis, there is growing evidence supporting their offlabel use in PCOS, and international guidelines now include them as a conditional recommendation. In women, the weight loss associated with these medications may trigger the return of spontaneous ovulation, making mistimed pregnancy a possibility. A key study by Sanz and Blázquez (back in 2011) demonstrated that both GLP-1 and the GLP-1 receptor are present in mouse embryos as early as embryonic day 6 (E6) and continue through the first trimester, as well as in pluripotent mouse embryonic stem cells. In these undifferentiated cells, GLP-1 modified the expression of endodermal, ectodermal, and mesodermal gene markers, as well as critical developmental signaling molecules. So, there is a concern about embryogenesis if inadvertent exposure to these meds occurs in early pregnancy. In this episode, we will summarize 2 recent and separate systematic reviews (March 2026; April 2026) on fetal/OB outcomes after periconceptional exposure. This builds on the Parker data set from 2025. One of these reviews, from April 2026, is also a meta-analysis. Listen in for details.

1. Ozbek L, Shah E, Al-Shiab R, Inal A, Guldan M, Afsar B, Covic A, Kanbay M. Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes. Diabetes Obes Metab. 2026 Mar 26. https://pubmed.ncbi.nlm.nih.gov/41885132/

2. Hakim J, Rajesh D, Tello J. Neonatal and Obstetric Outcomes Following Periconceptional Exposure to Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-analysis. AJOG; April 28, 2026; https://www.ajog.org/article/S0002-9378(26)00222-X/fulltext

3. Parker CH, et al. Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists' Use During Pregnancy: Safety Data From Regulatory Clinical Trials. Diabetes, Obesity & Metabolism. 2025.

HG: IVFs, Dextrose, & Ketones? (Lancet, 2026) May 01, 2026

Show notes

The belief that IV dextrose is necessary to clear ketones in hyperemesis gravidarum originated from a logical, and now known to be outdated, extrapolation of basic starvation ketosis physiology and the treatment paradigm for diabetic ketoacidosis (DKA). The original experiments that led to this conclusion go back to the 1960s (Foster data). Not only is this outdated, but it is also physiologically incorrect. We’ve learned a lot about IV fluid replacement about hyperemesis gravidarum in the last several years- in the last data review was in January 2026 in Lancet. Even the correction of hyponatremia has evolved. Should we be following urine ketones for patients being treated for HG? Is Dextrose needed? Listen in for details.

1. Nana M, Painter R, Williamson C et al. Hyperemesis gravidarum. The Lancet, Jan 2026; 407, 78-89

2. Clark SM, Zhang X, Goncharov DA. Inpatient Management of Hyperemesis Gravidarum. Obstet Gynecol. 2024 Jun 1;143(6):745-758. doi: 10.1097/AOG.0000000000005518. Epub 2024 Feb 1. PMID: 38301258.

3. Ayus JC, et al.Correction rates and clinical outcomes in hospitalized adults with severe hyponatremia: a systematic review and meta-analysis. JAMA Intern Med. 2025;185(1):38-51.

4. ACOG Clinical Epert Series: Inpatient Management of Hyperemesis Gravidarium. Obstet Gynecol; 2024

Allegra + Pepcid for PMDD? (AUDIO FROM INSTA VIDEO) Apr 30, 2026

Show notes

AUDIO EXCERPT from our recent Instragm post on this Social Media trend. Silly or Science? Listen in for details.

Novel LUS Compression Sutures for Previa Bleeding Apr 28, 2026

Show notes

Uterine compression sutures are effective, uterus-sparing techniques for managing severe postpartum hemorrhage (PPH) due to atony, avoiding hysterectomy. Keytypes include the B-Lynch suture (vertical, brace-like), Hayman suture (simplified vertical), and Pereira sutures (multiple, comprehensive sutures), and Cho Compression (quadrant square anterior to posterior closures), are applied when pharmacological methods fail. But these, while helpful with atony, do not address the LUS bleeding from previa which are below these applications. Even the O’Leary lateral sutures are often higher tha the bleeding and thin, anterior LUS affected by previa. Previa is a significant risk factor for PPH. In this episode, we will highlight 3 novel suture techniques which have been in print (TWO as recent as January 2026) which can be effective in stopping the LUS bleeding and avoiding hysterectomy. We will highlight the transverse circumferential purse string, the simple transverse Nausicaa suture, and theLUS WaveForm suture. These are easy to use and may be lifesaving.

1. Shih J, Li J, Kang J .The Nausicaä suture in the management of the placenta accreta spectrum. AJOG. Jan 2026: 233, S671-S688 S

2. Transverse Purse String Suture for Placenta Previa in the Presence of Previous Cesarean Section, Experience in Northern Borders Saudi Arabia. 2022

3. Zhou L et alWave compression suture: A modifieduterus-preserving treatment for placenta previa by reconstruction of the lower uterine segment. Medicine (Baltimore). 2026 Jan 30;105(5):e47468.

NEW ACOG Cervical Cancer Screening Info Apr 27, 2026

Show notes

(From our Instagram Video Post): A very quick recap of the brand new ACOG Cervcial Caner Screening Update from April 24, 2026.

Kerri's Keen Knowledge Apr 26, 2026

Show notes

Just a VERY QUICK episode in rsponse to my sweet friend's question. Kerri is an MFM in another part of the country and she had KEEN insights on our recent episode on "Best Perioperative ose for Ketorolac at CS". Listen in for more good stuff!

Best Dose of Ketorolac for C-Section Pain Prophylaxis? Apr 25, 2026

Show notes

The ACOG recommends a multimodal approach to postoperative pain that includes nonsteroidal NSAIDs, acetaminophen, and opioids. Ketorolac is a favored NSAID for postop pain control. However, the optimal dose of ketorolac after cesarean delivery has not been determined. In this episode, we will summarize a brand new randomized, controlled, single-blind trial of pregnant women undergoing cesarean delivery under regional anesthesia at a large academic medical center between June 2022 and October 2023. Enrolled participants were randomized to receive an initial loading dose of 60 mg (intervention) or 30 mg (control) of intravenous ketorolac in the operating room at the end of surgery.

1. Pharmacologic Stepwise Multimodal Approach for Postpartum Pain Management: ACOG Clinical Consensus No. 1. Obstetrics and Gynecology. 2021.

2. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstetrics and Gynecology. 2020.

3. Eid, Joe MD; Caplan, Madeleine MD; Goel, Nidhi MD; Poirier, Marie-Veronique MD; Montaine-O'Brien, Skyler MS; Rood, Kara M. MD; Costantine, Maged M. MD. Two Perioperative Ketorolac Dosing Regimens After Cesarean Delivery and Opioid Use: A Randomized Controlled Trial. O&G Open 3(2):e159, April 2026. | DOI: 10.1097/og9.0000000000000159

DIY PPH Tools: FOCUS, STUT, and/or U-CaVIT Apr 23, 2026

Show notes

Uterine hemorrhage remains a significant complication following abortion loss and in the postpartum period and contributes to substantial morbidity and mortality among pregnant patients. Although some FDA approved devices are on the market (Bakri balloon and Jada vacuum), they may be cost prohibited in some settings and/or some uterine cavities may be very small for either option, like after a mid-second trimester or early third trimester PPH. But every delivery unit has some form of suction tool and wall suction ability. This is where FOCUS*, STUT, and/or U-CaVIT come into play. And now there is new data on this from the AJOG (epub, April 2026). Listen in for details. (*Shout Out to Dr. Frank Jackson for his work on this as well).

1. Singata-Madliki et al. Suction Tube Uterine Tamponade Versus Uterine Balloon Tamponade for Treatment of Refractory Postpartum Hemorrhage: A Randomized Clinical Feasibility Trial. International Journal of Gynaecology and Obstetrics: The Official Organ of FIGO. July 2025. (South Africa)

2. Hofmeyr GJ, Singata-Madliki M. Novel Suction Tube Uterine Tamponade for Treating Intractable Postpartum Haemorrhage: Description of Technique and Report of Three Cases. BJOG : An International Journal of Obstetrics and Gynaecology. 2020

3. Jackson FI, Dilena NJ, Abelman SH, Blitz MJ, Gerber S. Hemorrhage management using a Foley catheter for uterine suction. Am J Obstet Gynecol. 2025 Nov;233(5):503-504.

4. ACOG Practice Bulletin No. 183: Postpartum Hemorrhage. Obstetrics and Gynecology. 2017.

5. Ranieri E, Kalimeris S, Ochsenbein N, Haslinger C, Vacuum-Induced Tamponade Using Urological Catheters for Postpartum Hemorrhage, American Journal of Obstetrics and Gynecology (2026), doi: https://doi.org/10.1016/j.ajog.2026.04.026

Our TOPPODCAST Picks

Follow Us

Stay Connected

Dr. Chapa’s OBGYN Clinical Pearls

Related Podcasts

Links

Stay Connected